ABSTRACT
INTRODUCTION
Wnt proteins, derived from Drosophila Wingless (Wg) and the mouse Int-1 genes, represent a large family of secreted cysteine-rich glycosylated proteins. This novel family of proteins is intimately involved in cellular signaling pathways that play a role in a variety of processes that involve embryonic cell patterning, proliferation, differentiation, orientation, adhesion, survival, and apoptosis 1 . Convincing evidence has established a crucial role for Wnt signaling in the maintenance and self-renewal of hematopoietic stem cells (HSC) 2 .
Constitutive activation of the Wnt pathway has been found in solid tumors as well as hematopoietic malignancies
3,4
. Over-activation of Wnt signaling cascade have been demonstrated to have a role in leukemia pathogenesis; and dysregulation of the pathway seems to lead to a gain of self-renewal capacity of progenitor cells, resulting in the promotion of different forms of leukemia
5-7
. WNT signaling is controlled by a number of natural Wnt antagonists that interfere with the ligand-receptor interaction, including members of the Dikkopf (DKK) family and the secreted frizzled-related protein (SFRP) family
8
. The human Dkk-3 gene, located on chromosome 11p15.1 is a recently found mortalisation-related gene. It has been determined that Dkk-3 possesses an antiproliferative activity against tumor cells, suggesting that Dkk-3 may function as a tumor suppressor, and that its effect seems to be mediated by its ability to antagonize Wnt signaling
9,10
. DKK-3 expression is largely attenuated in many immortalized and tumor derived cell lines 11 . The family of SFRPs belongs to a group of proteins antagonizing the Wnt signaling pathway by interaction with the Wnt receptor. The functional role of SFRPs in normal and malignant hematopoiesis has not yet been systematically investigated. Four of the five known SFRP genes are characterized by a CpG island in the promoter region.
A loss of function of tumor suppressor genes can result from mutations, chromosomal deletions or epigenetic dysregulation 12 . The best studied epigenetic mechanism for silencing of cancer-related genes is hypermethylation of CpG islands in the promoter region of genes. CpG island hypermethylation of tumor suppressor genes has been described in almost all solid and hematopoietic malignancies 13,14 . SFRP promoter hypermethylation is a frequent event in solid tumors, as was shown especially for SFRP1 and SFRP2 in 
Aim of the work:
This study aimed to analyze the frequency and the possible impact of epigenetic hypermethylation of the SFRP1 and DKK3 genes in acute leukemia patients. 
SUBJECTS & METHODS

RESULTS
The frequency of methylation in B-acute lymphoblastic leukemia (B-ALL) patients at diagnosis was 40% (12/30) for SFRP1, 40% (12/30) for DKK-3 and 13% (4/30) for methylation of both SFRP1 and DKK3. Hypermethylation of at least one gene occurred in 66.7% (20/30) of the B-ALL patients, while for acute myeloid leukemia (AML) patients, the frequency of methylation was 44% (22/50) for SFRP1, 36% (18/50) for DKK-3, 24% (12/50) for methylation of both SFRP1 and DKK3 and the frequency of methylation of at least one of these two genes was 56% (28/50). All the control subjects (100%) had no aberrant methylation in SFRP1 or DKK-3 genes. A significantly higher frequency of methylation was found in acute leukemia patients compared to control subjects, p value (0.001). While no significant difference was found by comparing B-ALL and AML groups as regards the frequency of SFRP1 or DKK-3 methylation, p value (>0.05).
The frequency of methylation in different B-ALL FAB categories was 75% (6/8), 62.5% (10/16), 50% (2/4) and 100% (2/2) for pro B, common B, pre B and mature B subtypes respectively, on the other-hand the AML group FAB categories showed a frequency of methylation of 25% (2/8), 55% (12/22), 100% (8/8), 75% (6/8), 0% (0/4) for M1, M2, M3, M4 and M5 respectively, as M0, M6 and M7 weren't encountered among patients group of the current study.
B-ALL patients were grouped according to their cytogenetic and molecular findings into; good [hyperdiploidy >50], intermediate [normoploidy and hyperdiploidy 47-50] , bad [hypodiploidy, BCR-ABL t(9; 22)] and unclassified (no available data) prognostic groups, the frequency of SFRP1 methylation among these groups was 50% (2/4), 28.5% (4/14), 60% (6/10) and 0% (0/2) respectively, while DKK-3 aberrant methylation frequency was 100% (4/4), 14% (2/14), 40% (4/10) and 100% (2/2) for the same ordered groups.
Cytogenetic and molecular grouping of AML patients into; Good [t (8; 21) and t (15;17)], bad (trisomy 8) and unclassified prognostic groups, revealed a frequency of SFRP1 methylation of 75% (12/16), 0% (0/6), and 35.5% (10/28) respectively, while the frequency of DKK-3 aberrant methylation was 37.5% (6/16), 66.7% (4/6), and 28.5% (8/28) for the same ordered groups.
B-ALL patients with M-SFRP1 had a significantly higher mean platelets count and a lower mean age compared to B-ALL patients with UM-SFRP1, P value (< 0.05), otherwise no significant difference, between M-SFRP1 and UM-SFRP1 ALL patients or between M-SFRP1 and UM-SFRP1 AML patients as regards any other clinical or hematological data, was encountered, P value (> 0.05).
As for B-ALL and AML patients with aberrant M-DKK3, they showed no significant difference as regards the clinical or hematological data when they were compared to UM-DKK3 B-ALL and AML patients respectively, P value (> 0.05).
AML patients with M-SFRP1 and UM-SFRP1 had a frequency of CD34 positivity of 9% (2/22) and 22% (6/28) respectively, while those with M-DKK3 and UM-DKK3 had a frequency of CD34 positivity of 11% (2/18) and 19% (6/32) respectively. 
NS: not significant P value (>0.05). N: number. Hb: hemoglobin. Plats: platelets. Lanes 2&3 represent control subjects, lanes 2a&3a denoting presence of UM-DKK3, lanes 2b,3b denoting absence of M-DKK3. Lanes 5,9,10 represent acute leukemia patients with unmethylated phenotype, lanes 5a,9a,10a denoting presence of UM-DKK3, lanes 5b,9b,10b denoting absence of M-DKK3. Lanes 4,6,7,8,11 represent acute leukemia patients with methylated phenotype, lanes 4a,6a,7a,8a,11a denoting presence of UM-DKK3, lanes 4b,6b,7b,8b,11b denoting presence of M-DKK3.
Figure 2: Electrophoretic analysis of SFRP1 promoter methylation status in control subjects and acute leukemia patients. Lane 1; molecular weight ladder 100-1000 bp. Lanes 2&3 represent control subjects, lanes 2a&3a denoting presence of UM-SFRP1, lanes 2b,3b denoting absence of M-SFRP1. Lanes 6,8,11 represent acute leukemia patients with unmethylated phenotype, lanes 6a, 8a, 11a denoting presence of UM-SFRP1, lanes 6b,8b,11b denoting absence of M-SFRP1. Lanes 4,5,7,9,10 represent acute leukemia patients with methylated phenotype, lanes 4a,5a,7a,9a,10a denoting presence of UM-SFRP1, lanes 4b,5b,7b,9b,10b denoting presence of M-SFRP1.
DISCUSSION
The The present study has addressed the question of the role and the frequency of epigenetic silencing of the Wnt antagonists SFRP1 and DKK3 in AML and B-ALL.
The frequency of aberrant methylation of SFRP1 among B-ALL patients' samples was 40% in the present study. In agreement with our study, nearly the same frequency (38 and 39.3%) of SFRP1 methylation in ALL were reported by two other studies 17,26 . The current study reported a frequency of 40% for DKK3 aberrant methylation among B-ALL patients. Roman-Gomez, et al. 25 reported that Dkk-3 methylation was detected at diagnosis in 33% (60 out of 183) of patients with ALL. Reviewing their study, the frequency of DKK-3 was calculated among B and T-ALL patients altogether while the frequency of M-DKK-3 among B-ALL was found to be 42% (64/152) in concordance to the present results.
Our reported SFRP1 methylation frequency, was 44% among AML patients, frequencies ranging between 29 and 34 % were reported by other studies 22,26,27,28 . The frequency of DKK3 aberrant methylation among AML patients was 36% in the present study. In contrast, a much lower (8%) and a much higher frequencies for DKK3 methylation among AML patients were reported by 2 other studies 28,29 respectively. Reviewing the study done by Griffiths et al. 28 who reported the 8% frequency for DKK3 methylation; we observed that relapsed AML and AML with antecedent MDS patients represented the main core of their study, on the contrary to the present study which was conducted on newly diagnosed patients. This may explain these discrepant results as treatment with chemotherapeutic agents, as the case in relapsed AML and AML with antecedent MDS, was reported to decrease methylation events 30 . The frequency of SFRP1 and/or DKK3 methylation varied among different AML and ALL, FAB subtypes with a special concern to M3, where 100% (8/8) of patients showed methylation of SFRP1 gene. M5 subtype included 4 patients, none of them showed methylation of any of SFRP1 or DKK3 genes.
No meaningful difference was encountered, when different B-ALL or AML prognostic cytogenetic groups were compared as regards the frequency of SFRP1 or DKK3 methylation, however the small sample size within these groups couldn't enable the statistical analysis.
In agreement with our study findings, Griffiths et al. 28 and RomanGomez et al.
17 reported no significant differences in the frequency of SFRP1 or DKK3 methylation between the normal karyotype group and other groups with abnormal karyotypes in AML and ALL patients respectively.
With the exception of higher mean platelets count, and lower mean age in B-ALL patients with M-SFRP1 compared to those with UM-SFRP1, no other significant difference was encountered, between M-SFRP1 and UM-SFRP1 B-ALL patients or between M-SFRP1 and UM-SFRP1 AML patients as regards any other clinical or hematological data.
In consistence to the present study findings, recent studies reported the same in ALL 17 and AML 22,28 . In contrast, Hou et al., 27 reported that AML patients with aberrant methylation of at least one Wnt inhibitor had lower WBC count and tended to be older than others. However, reviewing their study, they evaluated the methylation status of seven Wnt inhibitors genes (including SFRP1) and the previous findings were matched for AML patients with methylation of any of these genes.
We couldn't signal any significant difference in the clinical or hematological data of ALL or AML patients with aberrant M-DKK3 compared to those with UM-DKK3.
The current results are in agreement with those of RomanGomez et al. 17 ,25 who found no significant difference between ALL patients with methylated DKK3 and those with unmethylated DKK3, as regards different clinical and hematological data.
AML patients with M-SFRP1 and UM-SFRP1 had a frequency of CD34 positivity of 9% (2/22) and 21% (6/28) respectively, while those with M-DKK3 and UM-DKK3 had a frequency of CD34 positivity of 11% (2/18) and 19% (6/32) respectively.
In a trial to prove the impact of aberrant methylation of DKK3 and SFRP1 on their expression levels; Roman-Gomez et al. 25 quantitated the expression level of DKK3 besides the analysis of the DKK3 promoter methylation status in 183 ALL patients and reported that 60 ALL patients (33%) were methylated for DKK3 and all of them (100%) showed decreased Dkk3 expression; indicating that methylation within Dkk3 promoter strongly correlated with decreased constitutive expression of Dkk-3 in ALL patients. The same was confirmed for SFRP1 by another study 17 . Despite the findings reported by other studies as well as ours, that aberrant DKK3 or SFRP1 methylation wasn't linked with many of the clinical, hematological and cytogenetic variants that are correlated with prognosis of ALL and AML patients. However, studies that could retrospectively analyzed the patients data, could conclude a significant correlation between DKK3 and/or SFRP1 methylation with shorter disease free survival as well as overall survival in patients with ALL 17,25 , and AML 27 implicating DKK3 and SFRP1 methylation with poor prognosis.
There is growing evidence that the stem cell populations in various leukemias are resistant to standard therapies. Thus new therapies targeted against stem cells need to be identified.
Signal transduction pathways that regulate normal stem cell activity; like the Wnt pathway, could provide excellent therapeutic targets
21
. Therefore, in vitro treatment with demethylating agents, like 5-aza-2-deoxycytidine and decitabine that reverse the silencing effect of promoter methylation on Wnt inhibitory molecules like DKK3, SFRP1, may lead to down regulation of activated Wnt signaling pathway in patients with acute leukemia. This hypothesis was validated in ALL and AML 17,31 respectively. As DNA methylation changes could be used as a marker for minimal residual disease in AML
32
, monitoring of hypermethylation of SFRP1 and DKK3 genes may also serve for relapse prediction in ALL and AML after being validated by studies dealing with large cohort of acute leukemia patients in the follow up period.
In conclusion; our piece of work highlighted that SFRP1 and DKK3 silencing, by promoter methylation, is an early and a common event in the evolution of acute leukemia, methylation of SFRP1 and DKK3 may serve as potential independent biomarkers for early detection of acute leukemia. Patients with aberrant methylation phenotype may benefit from treatment with demethylating agents as that line of management expected to damp down the Wnt signaling activity and hence the activity of the disease. Our study also offers a preliminary basis for further studies to monitor hypermethylation of Wnt antagonists as a marker for minimal residual disease. 
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